Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Cytokinetics (CYTK) over the last 15 years, with Sep 2025 value amounting to $7.6 million.

  • Cytokinetics' Change in Accured Expenses rose 38.21% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year decrease of 52.22%. This contributed to the annual value of $14.2 million for FY2024, which is 17.08% down from last year.
  • Per Cytokinetics' latest filing, its Change in Accured Expenses stood at $7.6 million for Q3 2025, which was down 45.53% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Change in Accured Expenses registered a high of $32.1 million during Q4 2023, and its lowest value of -$14.4 million during Q1 2025.
  • Over the past 3 years, Cytokinetics' median Change in Accured Expenses value was $4.2 million (recorded in 2024), while the average stood at $3.5 million.
  • Data for Cytokinetics' Change in Accured Expenses shows a peak YoY increase of 9,253.56% (in 2023) and a maximum YoY decrease of 287.96% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Cytokinetics' Change in Accured Expenses stood at $1.2 million in 2021, then tumbled by 128.33% to -$351,000 in 2022, then skyrocketed by 9,253.56% to $32.1 million in 2023, then tumbled by 68.64% to $10.1 million in 2024, then soared by 38.21% to $7.6 million in 2025.
  • Its Change in Accured Expenses was $7.6 million in Q3 2025, compared to $14.0 million in Q2 2025 and -$14.4 million in Q1 2025.